HGH Fragment 176-191 and AOD-9604 — Adipocyte Research Lineage

Within the broader family of growth-hormone-derived research peptides, the HGH fragment 176-191 occupies a distinct niche. Unlike full-length somatotropin, which exerts pleiotropic effects on growth, glucose homeostasis, and tissue regeneration, this C-terminal fragment was engineered to isolate the lipolytic domain of the parent hormone. Its derivative, AOD-9604, became one of the first peptide candidates to reach Phase IIb clinical evaluation specifically for obesity. Together, they form a research lineage that has shaped contemporary understanding of how short peptide fragments can dissociate desired metabolic effects from systemic hormonal activity.

Frequently Asked Questions

What is HGH fragment 176-191?

HGH fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the C-terminus of the 191-residue human growth hormone molecule. Discovered in the late 1970s by researchers investigating the structure-activity relationships of pituitary somatotropin, the fragment retains the lipolytic and anti-lipogenic activity of the parent hormone while lacking the IGF-1-mediated growth-promoting and insulin-antagonizing effects, making it a tool compound for studying adipocyte metabolism.

How does AOD-9604 differ from HGH fragment 176-191?

AOD-9604 is a modified version of HGH fragment 176-191 developed by Monash University and Metabolic Pharmaceuticals in Australia. It incorporates an N-terminal tyrosine residue (Tyr-hGH177-191) to stabilize the molecule and improve pharmacokinetic properties in oral bioavailability investigations. While structurally similar, AOD-9604 was the candidate selected for clinical translation in AOD-9604 obesity research, advancing through Phase I and Phase IIb human trials.

What is the proposed mechanism of action?

Preclinical data suggest these peptides stimulate HGH fragment lipolysis through a non-classical pathway that does not require functional growth hormone receptors. Instead, the lipolytic effect appears to involve upregulation of beta-3 adrenoceptor expression on adipocytes, increased cyclic AMP signaling, and downstream activation of hormone-sensitive lipase. Anti-lipogenic effects have also been observed via inhibition of acetyl-CoA carboxylase.

Has AOD-9604 ever been approved as a drug?

No. Although AOD-9604 advanced through multiple Phase I and Phase IIb clinical trials sponsored by Metabolic Pharmaceuticals Ltd. between 2001 and 2007, the Phase IIb 24-week study did not meet its primary endpoint, and no marketing authorization for therapeutic indications has been granted.

Is HGH fragment 176-191 considered a “growth hormone” in regulatory terms?

The peptide is a synthetic growth hormone fragment derived from the C-terminus of somatotropin, but it lacks the receptor-binding domains responsible for classical growth hormone signaling. In regulatory contexts it is treated as a distinct research chemical rather than a recombinant growth hormone product. It is supplied strictly for laboratory research and is not approved for clinical use by the FDA, EMA, or any national agency.

How are these peptides typically reconstituted for in-vitro studies?

Researchers typically reconstitute lyophilized HGH fragment 176-191 or AOD-9604 in bacteriostatic or sterile water for cell-culture and bench experiments. The lyophilized peptide is shelf-stable at -20 degrees C; reconstituted solutions are generally aliquoted and stored at -80 degrees C to minimize freeze-thaw degradation. Specific reconstitution volumes depend entirely on the assay design and target concentration determined by the principal investigator.

What other peptides are studied alongside this lineage?

Researchers often compare HGH fragment 176-191 with growth-hormone-releasing peptides such as tesamorelin (a GHRH analogue), and with the newer incretin-class metabolic agents like tirzepatide and retatrutide, to compare distinct mechanisms of metabolic signaling. See our comparison of triple- and dual-agonist incretins for the receptor-pharmacology context.

Where can researchers find peer-reviewed literature?

Most foundational studies on HGH fragment 176-191 and AOD-9604 are indexed in PubMed and the NCBI literature database. Clinical trial records, including the Phase IIb obesity study, are listed on ClinicalTrials.gov. Reviews by Heffernan, Ng, Wijesundera, and colleagues at Monash provide the most comprehensive mechanistic synthesis.

1. Origins: Mapping the Lipolytic Domain of Somatotropin

The story of the HGH fragment 176-191 begins in the structural biology of pituitary growth hormone. Human somatotropin is a 191-amino-acid single-chain polypeptide with two intramolecular disulfide bridges. Early structure-function studies in the late 1970s and 1980s, notably by Frank Ng and colleagues at the Howard Florey Institute and later at Monash University, used proteolytic digestion and recombinant fragment synthesis to identify discrete regions of the molecule responsible for its disparate biological activities.

While the N-terminal and central regions encoded the somatogenic and lactogenic receptor-binding sites, the carboxyl tail — specifically residues 177 through 191 — was repeatedly implicated in HGH fragment lipolysis in adipose tissue. Wells, Heffernan, and Ng published a sequence of papers describing how a fragment encompassing this domain could reproduce the lipolytic and anti-lipogenic effects of intact GH in isolated rodent adipocytes without producing the IGF-1 elevation, hyperinsulinemia, or chondrocyte proliferation characteristic of full-length somatotropin.

1.1 Why dissociation matters

For decades, the clinical use of recombinant human growth hormone for metabolic indications was limited by its dose-dependent side effects: fluid retention, carpal tunnel syndrome, insulin resistance, and theoretical mitogenic concerns. A peptide that could trigger fat-cell-specific lipolysis without engaging the GH receptor at relevant doses would, in principle, sidestep these liabilities. This is the conceptual foundation of the entire lipolysis-research peptides research program built around the 176-191 fragment.

1.2 Sequence and synthesis

The peptide sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe in some numbering schemes, with two cysteine residues capable of forming an intramolecular disulfide bridge. The compound is manufactured today by standard solid-phase peptide synthesis (SPPS) using Fmoc chemistry, followed by HPLC purification to >98% purity and characterization by mass spectrometry. HGH fragment 176-191 from research-grade suppliers typically arrives as a white lyophilized powder with certificates of analysis covering identity, purity, water content, and endotoxin where relevant.

2. The Birth of AOD-9604

By the mid-1990s, Monash University researchers — led by Frank Ng and Heather Heffernan in collaboration with Metabolic Pharmaceuticals Ltd. — sought to translate the 176-191 fragment into a developable drug candidate. The challenge was twofold: the native fragment was rapidly cleared and exhibited limited oral bioavailability, both problematic for chronic metabolic therapy.

Their solution was AOD-9604, formally designated Tyr-hGH177-191 (sometimes written as Tyr-HGH 176-191 depending on numbering convention). The addition of a single tyrosine residue at the N-terminus was intended to improve metabolic stability and provide a handle for radiolabeling in pharmacokinetic studies. The “AOD” abbreviation stood for Anti-Obesity Drug. By 1999, AOD-9604 had been patented (US 6,068,997 and family members) and entered formal preclinical development.

2.1 Preclinical lipolysis studies

In rodent models, AOD-9604 reproduced the lipolytic profile of the parent fragment. Studies in ob/ob mice and high-fat-diet-induced obese mice examined body weight, adipose mass, and serum leptin endpoints. Heffernan and colleagues reported that chronic administration upregulated expression of beta-3 adrenoceptor mRNA in epididymal and inguinal white adipose depots — a finding that distinguished the peptide from purely catecholamine-mimetic lipolytic agents (Heffernan et al., Endocrinology, 2001; PubMed 11606467).

2.2 Safety pharmacology

An attractive feature reported in the early literature was the apparent lack of effect on serum IGF-1 or insulin sensitivity in those studies, suggesting the molecule was not engaging the classical GH receptor at relevant exposures. Acute toxicology in rodents and dogs identified no major target-organ findings, paving the way for first-in-human studies.

3. Clinical Development: Phase I Through Phase IIb

The clinical development of AOD-9604 represents one of the most thoroughly documented translational programs for a growth hormone fragment. Between 2001 and 2007, Metabolic Pharmaceuticals sponsored a series of trials examining oral and subcutaneous formulations.

3.1 Phase I — pharmacokinetics and safety

Early-phase studies in healthy volunteers characterized plasma exposure. The subcutaneous formulation demonstrated predictable absorption with a short circulating half-life (under 1 hour), while oral formulations showed limited but measurable bioavailability — sufficient for the sponsor to advance an oral candidate.

3.2 Phase IIa — proof of mechanism

A 12-week proof-of-concept study in overweight subjects examined surrogate markers of lipid metabolism and modest weight endpoints. Early results were sufficiently encouraging to justify the larger Phase IIb program.

3.3 Phase IIb — the pivotal study

The Phase IIb 24-week trial enrolled approximately 500 subjects across multiple Australian and US sites. The study did not meet its primary endpoint versus placebo, and the development program was subsequently restructured.

4. Mechanism of Action in Depth

The mechanism by which the HGH fragment 176-191 and AOD-9604 exert lipolytic activity remains a subject of ongoing investigation. Several non-mutually-exclusive pathways have been proposed.

4.1 Beta-3 adrenoceptor upregulation

The most consistently reported finding is upregulation of beta-3 adrenoceptor (ADRB3) expression on adipocytes following peptide exposure. The beta-3 receptor is the dominant adrenergic receptor on brown and beige adipose tissue and a major mediator of catecholamine-induced lipolysis. By increasing receptor density, the peptide may sensitize adipose tissue to endogenous sympathetic tone, indirectly amplifying lipolytic signaling rather than directly activating the receptor itself.

4.2 Adenylyl cyclase and cAMP signaling

Increased cyclic AMP levels have been measured in adipocytes treated with the fragment, consistent with downstream activation of protein kinase A (PKA) and phosphorylation of hormone-sensitive lipase (HSL) and perilipin. The net effect is mobilization of triglyceride stores and release of free fatty acids.

4.3 Anti-lipogenic activity via acetyl-CoA carboxylase

In parallel, the fragment has been reported to suppress lipogenesis through inhibition of acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in fatty acid synthesis. This dual action — promoting lipolysis while restraining lipogenesis — distinguishes the peptide from pure beta-agonists.

4.4 Independence from the GH receptor

Crucially, experiments in GH-receptor-knockout mice and in cell lines lacking functional GHR have demonstrated that the lipolytic effect persists, indicating a GH-receptor-independent mechanism. This finding underpins the safety rationale: classical GH-mediated side effects such as IGF-1 elevation and insulin antagonism would be expected to be minimal at the exposures studied.

5. Structural Pharmacology: Why Residues 176-191?

The choice of residues 176 through 191 reflects systematic deletion and substitution studies showing that this C-terminal region preserves lipolytic activity while eliminating somatogenic binding. Within the fragment, the disulfide bridge between Cys182 and Cys189 forms a small loop that appears critical for activity — reduction or alkylation of the cysteines abolishes the lipolytic effect.

5.1 Structure-activity relationships (SAR)

Alanine-scanning mutagenesis and truncation studies identified key residues for activity. The arginine residues at positions 178 and 183 appear important for the lipolytic phenotype, while the C-terminal phenylalanine contributes to receptor or target engagement. Substitution of these residues markedly reduces activity in adipocyte assays.

5.2 Comparison with parent hormone domains

6. Comparative Pharmacology: HGH Fragment vs Modern Metabolic Peptides

To situate the HGH fragment 176-191 lineage within the contemporary peptide landscape, it is useful to compare it side-by-side with other compounds currently studied for metabolic and adipose-related endpoints.

6.1 Mechanism contrast

Whereas AOD-9604 and the parent HGH fragment 176-191 act peripherally on adipocyte machinery, modern incretin-based peptides such as tirzepatide and retatrutide act primarily on central appetite circuitry and pancreatic islets. Tesamorelin occupies a third niche, acting on the pituitary to stimulate endogenous pulsatile GH secretion — see our dedicated tesamorelin research guide for that pathway.

6.2 Clinical comparison

Head-to-head clinical comparison data are not available. The Phase IIb AOD-9604 trial did not meet its primary endpoint, and the obesity field’s focus subsequently shifted toward incretin pharmacology.

7. Pharmacokinetics and Formulation Considerations

Short circulating half-lives are the principal pharmacokinetic challenge for both HGH fragment 176-191 and AOD-9604. Subcutaneous administration produces rapid absorption and elimination, requiring frequent administration in animal models to maintain pharmacologically relevant exposure.

7.1 Oral bioavailability efforts

A significant component of the AOD-9604 development program focused on oral formulations using enteric coatings and absorption enhancers. Bioavailability remained modest but reproducible, sufficient for proof-of-concept human studies. The translational lesson — that oral peptide delivery requires either novel chemistry, permeation enhancers, or alternative routes — has been internalized across the modern peptide field.

7.2 Stability and handling in the laboratory

Lyophilized peptide is generally stable for 24–36 months at -20 degrees C. Reconstituted solutions are typically used within 14–30 days when refrigerated, with single-use aliquots stored at -80 degrees C for longer-term studies. Repeated freeze-thaw cycles should be minimized; oxidation of cysteine residues is the principal degradation pathway.

8. Preclinical Parameters Reported in the Literature

The following parameters reflect values reported in published preclinical research only and are cited for context. They are not recommendations and have no application to human use.

• Isolated rat adipocyte assays: typically 10^-9 to 10^-6 M peptide concentration to characterize lipolytic dose-response
• Cell culture (3T3-L1 adipocytes): 100 nM to 1 micromolar for differentiation and lipid-accumulation assays

9. Where the Field Stands in 2026

After the Phase IIb result, AOD-9604 was not developed further as a therapeutic. The molecule remains widely used as a tool compound in academic adipocyte biology, particularly for studies probing the dissociation of GH receptor signaling from peripheral metabolic effects.

9.1 Renewed interest in non-incretin mechanisms

Ironically, the dominance of incretin-based obesity therapeutics has renewed interest in non-overlapping mechanisms. As GLP-1- and GIP-based agents saturate the metabolic space, sponsors are again examining peripheral lipolytic mechanisms — including beta-3 adrenoceptor agonism (mirabegron), uncoupling-protein-1-mediated thermogenesis, and adipocyte-specific signaling — for combination strategies. The HGH fragment 176-191 lineage provides important mechanistic precedent for these inquiries.

9.2 Combinatorial research designs

Some current academic protocols co-administer the HGH fragment with incretin agents in rodent models to ask whether peripheral lipolysis and central anorexia produce additive or synergistic effects on body composition. While such studies remain preclinical, they illustrate how the 176-191 lineage remains a useful pharmacological reagent. For background on incretin pharmacology, see our retatrutide vs tirzepatide vs semaglutide comparison.

10. Quality Control: What Researchers Should Expect on a CoA

Procurement of research-grade HGH fragment 176-191 or AOD-9604 should always be accompanied by a Certificate of Analysis (CoA). Critical specifications include:

• Identity: Mass spectrometry (typically MALDI-TOF or ESI-MS) confirming the theoretical molecular weight (approximately 1817 Da for HGH 176-191; approximately 1815 Da for AOD-9604 depending on counter-ion).
• Purity: Reversed-phase HPLC purity ≥98% area at 214 nm.
• Water content: Karl Fischer titration, typically <5%.
• Acetate content: Where peptide is supplied as an acetate salt, counter-ion content should be quantified.
• Endotoxin: Limulus amebocyte lysate (LAL) testing where in-vivo use is anticipated.
• Appearance: White to off-white lyophilized powder.

For an overview of best practices across the broader peptide research workflow, including reconstitution, storage, and assay design, see our complete guide to research peptides for 2026.

11. Regulatory and Compliance Notes

The HGH fragment 176-191 and AOD-9604 are not approved as drugs by the U.S. Food and Drug Administration, the European Medicines Agency, or any other national regulatory authority for therapeutic use in humans. Their distribution is permitted only for laboratory research purposes. Both peptides appear on the World Anti-Doping Agency Prohibited List under the broader category of growth hormone fragments and their releasing factors (see WADA prohibited substances list, S2 class).

Institutional investigators planning in-vivo studies should ensure that protocols are reviewed by their Institutional Animal Care and Use Committee (IACUC) or equivalent body and that handling, storage, and disposal comply with local biosafety and chemical-hygiene regulations.

12. Key Takeaways

• The HGH fragment 176-191 is the C-terminal portion of human growth hormone, retaining lipolytic activity while lacking somatogenic effects.
• AOD-9604 is a Tyr-modified analogue that advanced through Phase I and Phase IIb obesity trials sponsored by Metabolic Pharmaceuticals; the Phase IIb did not meet its primary endpoint.
• The proposed mechanism for HGH fragment lipolysis centers on upregulation of beta-3 adrenoceptor expression, increased cAMP, hormone-sensitive lipase activation, and acetyl-CoA carboxylase inhibition.
• The peptides act independently of the classical growth hormone receptor at the exposures studied.
• Modern lipolysis-research peptides based on incretin pharmacology (tirzepatide, retatrutide) have largely replaced GH-fragment approaches in clinical development, but the GH fragment lineage retains value as a mechanistic tool compound.
• Quality research-grade peptide is supplied as a lyophilized powder with HPLC purity ≥98% and full CoA characterization.
• All work with the growth hormone fragment family must remain strictly within laboratory research contexts under appropriate institutional oversight.

13. Selected Literature and Citations

The following references and search anchors capture the foundational and review literature on the HGH fragment 176-191 and AOD-9604 program:

• Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001 — PubMed 11606467
• Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000 — PubMed search: Ng FM AOD9604
• Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 2001 — PubMed search
• Ng FM, Bornstein J. Hyperglycaemic action of synthetic C-terminal fragments of human growth hormone. Nature. 1978; 271:683-685 — historical reference, PubMed search
• Wijesundera DN, Buckingham JC, Stewart JM. Pharmacological characterization of AOD9604 in adipose tissue. Diabetes, Obesity and Metabolism. PubMed search: AOD9604 adipose
• Metabolic Pharmaceuticals Ltd. AOD9604 Phase IIb trial. Clinical trial records — ClinicalTrials.gov search
• Stier H, Vos E, Kenley D. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. PubMed search
• Comprehensive bibliographic search across the topic: PubMed: AOD-9604 and PubMed: HGH fragment 176-191
• WADA Prohibited List, S2 Peptide Hormones — World Anti-Doping Agency
• NCBI Bookshelf — Endocrinology reviews on growth hormone structure-function: NCBI Bookshelf

14. Related Research from Axion

Researchers studying the HGH fragment 176-191 and AOD-9604 lineage frequently work in parallel with related peptide classes. The following resources may be of interest:

• Tesamorelin Research Guide — GHRH-analogue mechanism in lipodystrophy and visceral adipose tissue
• Retatrutide vs Tirzepatide vs Semaglutide — modern incretin-based comparison
• Complete Guide to Research Peptides 2026 — handling, quality control, and laboratory workflows

For product information, see HGH fragment 176-191, AOD-9604, tesamorelin, tirzepatide, and retatrutide in the Axion Research Peptides catalog.

15. Conclusion

The HGH fragment 176-191 and its tyrosine-modified analogue AOD-9604 represent a foundational chapter in the translational pharmacology of peptide-based metabolic agents. By isolating the lipolytic domain of growth hormone, Monash University and Metabolic Pharmaceuticals demonstrated that selective dissociation of hormonal activities was achievable through fragment chemistry — a principle that has informed subsequent peptide engineering across endocrinology and metabolism. Although the Phase IIb obesity result did not deliver a marketed product, the molecule remains an instructive tool compound for studying beta-3 adrenoceptor dynamics, adipocyte lipolytic machinery, and the structural basis of growth-hormone receptor independence. Within the broader category of lipolysis-research peptides, the HGH fragment 176-191 lineage retains scientific relevance even as incretin-class agents dominate modern clinical practice. For research teams working on adipocyte biology, the HGH fragment 176-191 peptide and AOD-9604 continue to serve as well-characterized, mechanistically distinct reagents complementing newer pharmacology.

These products are sold strictly for laboratory research purposes only. Not for human consumption, diagnosis, or treatment. Statements have not been evaluated by the FDA, EMA, or any regulatory agency. Researchers must comply with all applicable laws and institutional review requirements.